Clinical trials
Solid Tumor clinical trials
Below are recruiting solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,667 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT05288205RecruitingPhase 1/Phase 2
JAB-21822 plus JAB-3312 for KRAS G12C solid tumors
This Phase 1/2a trial tests two investigational pills (JAB-21822 and JAB-3312) in people with advanced solid cancers that have a KRAS G12C mutation. It’s for cases where standard treatments have failed or aren’t suitable, to see if the drugs can shrink tumors and improve outcomes.
Hefei, AnhuiAges 18 years+ - NCT05267626RecruitingPhase 1/Phase 2
AU-007 antibody for hard-to-remove or spread skin and lung cancers
This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.
Miami, FloridaAges 18 years+ - NCT05203172RecruitingPhase 4
Continued access to encorafenib and binimetinib for prior trial participants
This study lets people who were already getting encorafenib and binimetinib in an earlier trial keep taking these medicines if they are doing well on them. It provides a way to continue treatment without a gap.
Phoenix, ArizonaAges 18 years+ - NCT05208762RecruitingPhase 1
PD-L1 antibody drug study for advanced lung and head/neck cancers
This Phase 1 trial tests a new experimental drug (PF-08046054/SGN-PDL1V) in people with advanced solid tumors that have not responded to standard treatment or can’t use it. It is designed to see how the drug works and how safe it is, with a focus on tumors that have PD-L1 seen on prior lab testing.
Birmingham, AlabamaAges 18 years+ - NCT05245136Recruiting
Blood test study for advanced cancer monitoring
This study uses a blood test (liquid biopsy) to look for tumor DNA in patients with advanced cancer. It aims to see if this test can help doctors monitor the cancer and make better treatment decisions.
Augsburg, BavariaAges 18 years+ - NCT05232409RecruitingPhase 1
Zeaxanthin in metastatic cancer, alone or with pembrolizumab
This Phase 1 study tests whether zeaxanthin is safe and what dose to use in people with metastatic cancer. It also studies zeaxanthin together with pembrolizumab (an immunotherapy) to see if the combination is tolerable after cancer has progressed despite PD-1/PD-L1 treatment.
Paramus, New JerseyAges 18–99 - NCT05223608Recruiting
Study of people starting immunotherapy for solid tumors
This study follows people who are starting their first immune “checkpoint” treatment for a solid cancer. It collects clinic information and lab results to understand how patients respond and what factors matter most.
Lille, Hauts-de-FranceAges 18 years+ - NCT05250284Recruiting
Study of cancer care support for working men’s well-being
This study looks at how cancer treatment care affects the well-being of working men during the first months after diagnosis. It may help identify ways to support you while you continue working or plan to return to work.
Aurora, ColoradoAges 21–70 - NCT05166694Recruiting
Personalized testing to check drug interactions and gene effects
This study uses personalized information to help understand how your current medicines interact with each other and with your genes. It may help your care team choose safer, more effective medication plans for you.
Chicago, IllinoisAges 18 years+ - NCT05151718Recruiting
Study of ependymoma treatment resistance in children
This trial looks at why ependymoma can resist (be harder to treat) after radiation or treatment. It studies children who are already being followed in specific existing programs, which may help researchers find better treatment approaches in the future.
ToulouseAges Up to 25 years - NCT05098132RecruitingPhase 1/Phase 2
STK-012 drug for advanced lung cancer and other tumors
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
Tucson, ArizonaAges 18 years+ - NCT05120596RecruitingPhase 1/Phase 2
Testing an immune-targeting drug by direct injection into tumors
This Phase 1/2 trial tests T3P, a new treatment given directly into reachable solid tumors, to see if it is safe and can help shrink tumors. It is for adults with advanced cancers when no curative treatment is available.
Pamplona, NavarreAges 18–74 - NCT05103683RecruitingPhase 1
First-time test of TORL-1-23 for advanced solid tumors
This early study tests a new drug (TORL-1-23) in people with advanced solid cancers. It aims to find the safest dose and see how the tumor responds.
Fullerton, CaliforniaAges 18 years+ - NCT05093335RecruitingEarly Phase 1
PET scan test for CXCR4 in many relapsed cancers
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
New York, New YorkAges 18 years+ - NCT04353375RecruitingPhase 2/Phase 3
Study drug for FGFR2-mutated bile duct cancer
This trial tests HMPL-453 to treat advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has an FGFR2 change. It may help shrink tumors or control the disease in people whose cancer has not responded well to prior treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05003895RecruitingPhase 1
CAR-T for solid tumors with high GPC3 protein
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
Bethesda, MarylandAges 18–120 - NCT04999761RecruitingPhase 1
Study testing new drug combinations for advanced cancers
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
AichiAges 18 years+ - NCT04969315RecruitingPhase 1/Phase 2
Study of two new drugs for advanced kidney, prostate, lung, or mesothelioma cancer
This study tests two new study drugs (TT-4 and TT-10) alone and together in people with certain advanced cancers that have not responded to standard treatments. The goal is to see if these drugs are safe and effective in shrinking tumors or slowing the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT04932525Recruiting
Cancer profiling study for adults with eligible tumors
This study helps doctors better understand your cancer by doing tumor/cancer profiling as part of research. If you qualify, your participation may help improve how cancers are studied and matched with future treatments.
Villejuif, Val de MarneAges 18 years+ - NCT04906434RecruitingPhase 1
Study of ABSK-011 for advanced solid tumors
This early-phase study tests how safe ABSK-011 is, what side effects it causes, and how the body processes the drug. It may help certain patients with advanced solid cancers (including some liver cancer cases) whose tumors have specific test results.
Phoenix, ArizonaAges 18–75 - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Clovis, CaliforniaAges 18 years+ - NCT04916990Recruiting
Care program for rural adults with several lung and head cancers
This study looks at how to improve care for adults with certain cancers who live in rural areas and may face access problems. It mainly focuses on people receiving cancer treatment at specific Colorado-area hospitals, and who are uninsured or underinsured.
Aurora, ColoradoAges 18–99
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor?
- Yes. Clin2 currently lists 1,667 recruiting solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.